Volume 17, Number 2—February 2011
Surface Layer Protein A Variant of Clostridium difficile PCR-Ribotype 027
Highlight and copy the desired format.
|EID||Spigaglia P, Barbanti F, Mastrantonio P. Surface Layer Protein A Variant of Clostridium difficile PCR-Ribotype 027. Emerg Infect Dis. 2011;17(2):317-319. https://dx.doi.org/10.3201/eid1702.100355|
|AMA||Spigaglia P, Barbanti F, Mastrantonio P. Surface Layer Protein A Variant of Clostridium difficile PCR-Ribotype 027. Emerging Infectious Diseases. 2011;17(2):317-319. doi:10.3201/eid1702.100355.|
|APA||Spigaglia, P., Barbanti, F., & Mastrantonio, P. (2011). Surface Layer Protein A Variant of Clostridium difficile PCR-Ribotype 027. Emerging Infectious Diseases, 17(2), 317-319. https://dx.doi.org/10.3201/eid1702.100355.|
To the Editor: Rates and severity of Clostridium difficile infection (CDI) have recently increased worldwide and correlate with dissemination of hypervirulent epidemic strains designated PCR-ribotype 027. CDI caused by this PCR-ribotype is characterized by strong toxin A and B production, presence of binary toxin genes, and, usually, a high level of resistance to fluoroquinolones (1).
The mechanisms by which C. difficile colonizes the gut during infection are poorly understood. In addition to the toxins, surface protein components are undoubtedly involved. In particular, the surface layer (S-layer) mediates adhesion to enteric cells (2), but other functions have been proposed for this S-layer structure: it may act as a molecular sieve, protect against parasitic attack, or be a mechanism to evade the host immune system (3). Furthermore, the C. difficile S-layer is the predominant surface antigen and is among the main potential candidates for multicomponent vaccines against CDI (4,5). Composed of 2 major components, the C. difficile S-layer has high and low molecular weight proteins (HMW and LMW, respectively), which are formed from the posttranslational cleavage of a single precursor, surface layer protein A (slpA) (6). Different variants of the slpA gene have been identified in C. difficile (7).
The complete genome sequences of 2 C. difficile PCR-ribotype 027 strains (CD196, a nonepidemic strain isolated in France in 1985, and R20291, isolated from an outbreak in Stoke Mandeville, UK, in 2006) have been recently deposited in GenBank (accession nos. FN538970 and FN545816, respectively) (8). We analyzed the slpA gene of these strains by using the National Center for Biotechnology Information BLAST server (www.ncbi.nlm.nih.gov/blast)and the European Bioinformatics Institute ClustalW server (www.ebi.ac.uk/clustalw). Both strains showed a new and identical slpA nucleotide sequence. To determine if the new variant was conserved among PCR-ribotype 027 strains, we characterized 8 additional epidemic strains belonging to this PCR-ribotype that were isolated in different geographic regions and years and showed different patterns of resistance to erythromycin and moxifloxacin. Three strains, AI13, AII6, and AIII8, were isolated in 3 hospitals in Belgium during a European prospective study conducted in 2005 (9). C. difficile DI12 was isolated in Ireland during the same study. C. difficile GII7 and LUMC46 were isolated in the Netherlands in 2005 and 2008, respectively. C. difficile M43 and A422 were isolated in Calgary (Canada) in 2001 from 2 outbreaks.
Six strains were resistant to erythromycin (MICs >256 mg/L) and moxifloxacin (MICs 12–256 mg/L). AIII8 was resistant to erythromycin (MIC >256 mg/L) and intermediately resistant moxifloxacin (MIC = 6 mg/L), whereas CD196, LUMC46, and A422 were susceptible to both drugs.
The slpA genes of all strains were amplified by PCR mapping. Nine primers were designed on the slpA region to obtain 10 overlapping PCR products. The positions of the primers on the reference sequence FN545816 were 3161991–31612012, 3162346–3162365, 3162728–3162746, 3162746–3162728, 3163514–3163495, 3164222–3164205, 3163264–3163284, 3163284–3163264, and 3164518–3164499. Target amplification was performed by an initial denaturation at 94°C for 5 min, then 30 cycles of 94°C for 1 min, 50°C for 1 min, and 72°C for 1 min. Sequence assembly was performed by using DNAStar Lasergene version 8.0 software (DNAStar, Madison, WI, USA). The protein analysis was performed by using the SignalP 3.0 server (www.cbs.dtu.dk/services/SignalP/) and the ExPASy Proteomics server (www.expasy.ch/tools/pi_tool.html). Amino acid comparisons were accomplished by using ClustalW (www.ebi.ac.uk/clustalw), and the output was used for construction of the phylogenetic tree by TreeView version 1.6.6 (http://en.bio-soft.net/tree/TreeView.html). All PCR-ribotype 027 strains showed the same slpA gene nucleotide sequence. The slpA precursor encoded by this gene contained a signal peptide, and its cleavage site was located between aa 24 and aa 25. The cleavage of the slpA precursor into LMW and HMW proteins was predicted between aa 342 and aa 343 (N terminal to an Ala amino acid residue and C-terminal to a consensus motif Thr-Lys-Ser). The molecular masses of the LMW and HMW proteins were 33.871 kDa and 44.174 kDa, respectively. These protein sizes were confirmed by sodium dodecyl sulfate polyacrylamide gel electrophoresis, after a low pH glycine extraction (data not shown). The phylogenetic tree (Figure), obtained by comparison with the amino acid sequences of other PCR ribotypes (6), showed that C. difficile strain 027 slpA was strongly related (identity 89%) to that of strains belonging to the epidemic PCR-ribotype 001. In particular, the identity between the 2 PCR ribotypes was 100% for the HMW proteins and 77% for the LMW proteins.
This study provides convincing evidence that the S-layer is well conserved in C. difficile PCR-ribotype 027 strains and has high identity with the slpA of the epidemic PCR-ribotype 001. Because C. difficile PCR-ribotypes 027 and 001 are the most frequently isolated strains from severe CDIs across both North America and Europe (9,10), the result obtained suggests that the S-layer of these virulent strains presents peculiar and common characteristics that could be an advantage for these bacteria during the infection process.
We thank the following participants of the 2005 European Prospective Study on Clostridium difficile: M. Delmé, D. Drudy, and E. Kuijper for providing strains AI13, AII6, AIII8, DI12, and GII7; E. Kuijper for providing strain LUMC46; and T. Louie for providing strains M43 and A422. We also thank Tonino Sofia for editing the manuscript.
This work was partially supported by the European Community project “The Physiological Basis of Hypervirulence in Clostridium difficile: A Prerequisite for Effective Infection Control”—HEALTH-F3-2008-223585.
- O’Connor JR, Johnson S, Gerding DN. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology. 2009;136:1913–24.
- Calabi E, Calabi F, Phillips AD, Fairweather NF. Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues. Infect Immun. 2002;70:5770–8.
- Sára M, Sleytr UB. S-layer proteins. J Bacteriol. 2000;182:859–68.
- Pantosti A, Cerquetti M, Viti F, Ortisi G, Mastrantonio P. Immunoblot analysis of serum immunoglobulin G response to surface proteins of Clostridium difficile in patients with antibiotic-associated diarrhea. J Clin Microbiol. 1989;27:2594–7.
- Ausiello CM, Cerquetti M, Fedele G, Spensieri F, Palazzo R, Nasso M, Surface layer proteins from Clostridium difficile induce inflammatory and regulatory cytokines in human monocytes and dendritic cells. Microbes Infect. 2006;8:2640–6.
- Eidhin DN, Ryan AW, Doyle RM, Walsh JB, Kelleher D. Sequence and phylogenetic analysis of the gene for surface layer protein, slpA, from 14 PCR ribotypes of Clostridium difficile. J Med Microbiol. 2006;55:69–83.
- Fagan RP, Albesa-Jové D, Qazi O, Svergun DI, Brown KA, Fairweather NF. Structural insights into the molecular organization of the S-layer from Clostridium difficile. Mol Microbiol. 2009;71:1308–22.
- Stabler RA, He M, Dawson L, Martin M, Valiente E, Corton C, Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol. 2009;10:R102.
- Barbut F, Mastrantonio P, Delmée M, Brazier J, Kuijper E, Poxton I. European Study Group on Clostridium difficile (ESGCD). Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect. 2007;13:1048–57.
- Cheknis AK, Sambol SP, Davidson DM, Nagaro KJ, Mancini MC, Hidalgo-Arroyo GA, Distribution of Clostridium difficile strains from a North American, European, and Australian trial of treatment for C. difficile infections: 2005–2007. Anaerobe. 2009;15:230–3.
FigureCite This Article
- Page created: July 08, 2011
- Page last updated: July 08, 2011
- Page last reviewed: July 08, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)